Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.41 +1.26%
EPS Growth %: +400.0%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
CCEL, SLP, TMQ, More
EPS Growth %: +400.0%
Financial Fact:
GROSS PROFIT (LOSS): 422K
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.
Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
- SanDisk surges as Meta memo confirms multi-year flash storage deal
- Simply Good Foods (SMPL) Tops Q3 EPS by 7c; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
